In vivo distribution of adoptively transferred indium- 111- labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma

Journal of the National Cancer Institute

Volumn 81, Issue 22, 1989, Pages 1709-1717

  Griffith, Kean D ^a   Read, Elizabeth J ^a   Carrasquillo, Jorge A ^a   Carter, Charles S ^a   Yang, James C ^a   Fisher, Beth ^a   Aebersold, Paul ^a   Packard, Beverly S ^a   Yu, Monica Y ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INDIUM 111; INTERLEUKIN 2; RADIOISOTOPE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; BIOPSY; CELLS, CULTURED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; HUMAN; IMMUNOTHERAPY; INDIUM RADIOISOTOPES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGE; SKIN NEOPLASMS;

EID: 0024367332     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/81.22.1709     Document Type: Article

References (48)

1. Furth ME, Aldrich TH, Cordon-Cardo C: Expression of ras protooncogene proteins in normal human tissues. Oncogene 1:47-58, 1987
2. Beer DG, Zweifel KA, Simpson DP, et al: Specific gene expression during compensatory renal hypertrophy in the rat. J Cell Physiol 131:29-35, 1987
3. Zajchowski D, Band V, Panzie N, et al: Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res 48:7041-7047, 1988
4. Tandon AK, Clark GM, Ullrich A, et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1988
5. Kraus MH, Popescu NC, Amosbaugh SC, et al: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610, 1987
6. Vuver MF, Peterse JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer. N Engl J Med 319:1239-1245, 1988
7. Dollbaum C, Creasy AA, Dairkee SH, et al: Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin. Proc Natl Acad Sci USA 85:4740-4744, 1988
8. Santos GF, Scott GK, Lee WMF, et al: Estrogen-induced post- transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J Biol Chem 263:9565-9568, 1988
9. Tabin CJ, Bradley SM, Bargmann El, ET al: Mechanism of activation of a human oncogene. Nature 300:143-149, 1982
10. Suggs SV, Wallace RB, Hirose T, et al: Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for human /32-microglobulin. Proc Natl Acad Sci USA 78:6613-6617, 1981
11. Benz C, Cadman C: Biochemical alterations during unperturbed suspension growth of L1210 cells. Cancer Res 41:157-163, 1981
12. McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10:5-9, 1987
13. Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 208:121-135, 1988
14. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor- infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676-1680, 1988
15. Rosenberg SA, Speiss P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986
16. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6:839-853, 1988
17. Yang JC, Rosenberg SA: Current approaches to the adoptive immunotherapy of cancer. In Cancer Metastasis (Prodi G, Liotta LA, Lollini P, et al, eds). New York: Plenum Press 1988, p 459
18. Muul LM, Spiess PJ, Director EP, et al: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989-995, 1987
19. Itoh K, Tilden AB, Balch CM: Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46:3011-3017, 1986
20. Fisher B, Packard BS, Read EF, et al: Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7:250-261, 1989
21. Topalian SL, Muul LM, Solomon C, et al: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127-141, 1987
22. Carter CS, Leitman SF, Cullis H, et al: Use of a continuous-flow cell separator in density gradient isolation of lymphocytes. Transfusion 27:362-365, 1987
23. Muul LM, Nason-Burchenal K, Carter CS, et al: Development of an automated closed system for generation of human lymphokine activated killer (LAK) cells for use in adoptive immunotherapy. J Immunol Methods 101:171-181, 1987
24. Issekutz T, Chin W, Hay JB: Measurement of lymphocyte traffic with indium-111. Clin Exp Immunol 39:215-221, 1980
25. Butcher EC, Ford WL: Following cellular traffic: Methods of labelling lymphocytes and other cells to trace their migration in vivo, In Handbook of Experimental Immunology, 4th ed. (Herzenberg LA, Weir DM, eds). Oxford: Blackwell, 1986
26. Michie SA, Rouse RV: Study of murine T-cell migration using the Thy-1 allotypic marker. Demonstration of antigen-specific homing to lymph node germinal centers. Transplantation 46:98-104, 1988
27. Rannie GH, Thakur ML, Ford WL: An experimental comparison of radioactive labels with potential application to lymphocyte migration studies in patients. Clin Exp Immunol 29:509-514, 1977
28. Zatz MM, Lance EM: The distribution of chromium 51-labelled lymphoid cells in the mouse. A survey of anatomical compartments. Cellular Immunol 1:3-17, 1970
29. Balaban EP, Simon TR, Sheehan RG, et al: Effect of the radiolabel mediator tropolone on lymphocyte structure and function. J Lab Clin Med 107:306-314, 1986
30. Butcher EC, Scollay RG, Weissman IL: Organ specificity of lymphocyte migration: Mediation by highly selective lymphocyte interaction with organ-specific determinants on high endothelial venules. Eur J Immunol 10:556-561, 1980
31. Hamann A, Jablonski-Westrich D, Duuvestun A, et al: Evidence for an accessory role of LFA-1 in lymphocyte-high endothelium interaction during homing. J Immunol 140:693-699, 1988
32. Jung TM, Gallatin WM, Weissman IL, et al: Downregulation of homing receptors after T cell activation. J Immunol 141:4110-4117, 1988.
33. Hamann A, Jablonski-Westrich D, Scholz K, et al: Regulation of lymphocyte homing: I. Alterations in homing receptor expression and organ-specific high endothelial venule binding of lymphocytes upon activation. J Immunol 140:737-743, 1988
34. Stevens SK, Weissman IL, Butcher EC: Differences in the migration of B and T lymphocytes: Organ-selective localization in vivo and the role of lymphocyte-endothelial cell recognition. J Immunol 128:844851, 1982
35. Vukic R, Tomek R, Culo F, et al: The effectiveness of intravenously administered immune lymphoid cells against intraperitoneally growing tumor correlates with their homing in the recipients’ lymphoid organs. Eur J Cancer Clin Oncol 24:151-159, 1988
36. Chang AE, Sugarbaker PH: Preferential homing of passively transferred T cells into skin allografts of mice. Transplantation 28:247-252, 1979
37. Mule JJ, Jones FR, Hellstrom I, et al: Selective localization of radiolabeled immune lymphocytes into syngeneic tumors. J Immunol 123:600-606, 1979
38. Mule JJ, Hellstrom I, Hellstrom KE: Cell surface phenotypes ofradiolabeled immune long-lived lymphocytes that selectively localizein syngeneic tumors. Am J Pathol 107:142-149, 1982
39. Lotze MT, Line BR, Mathisen DJ, et al: The in vivo distributionof autologous human and murine lymphoid cells grown in T cellgrowth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 125:1487-1493, 1980
40. Mazumder A, Eberlein TJ, Grimm EA, et al: Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53:896-905, 1984
41. Morita T, Yonese Y, Minato N: In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra- arterial infusion in patients with renal cell carcinoma. JNCI 78:441450, 1987
42. Mukherji B, Arnbjarnarson O, Spitznagle LA, et al: Biodistribution of IN-111 labeled tumor sensitized autologous lymphocytes in cancer patients. Prog Clin Biol Res 244:325-334, 1987
43. Akporiaye ET, Kudalore M, Stevenson AP, et al: Isolation and reactivity of host effectors associated with the manifestation of concomitant tumor immunity. Cancer Res 48:1153-1158, 1988
44. Ames IH, Gagne GM, Garcia AM, et al: Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice. Cancer Immunol Immunother 29:93-100, 1989.
45. Farrer PA, Saha GB, Shibata HN: Evaluation of In-111-transferrin for the detection of tumors. J Nucl Med 13:429, 1972
46. Goodwin DA, Goode R, Brown L, et al: 111-In-labeled transferrin for the detection of tumors. Radiology 100:175-179, 1971
47. Lavender JP, Goldman JM, Arnot RN, et al: Kinetics of indium-111 labelled lymphocytes in normal subjects and patients with Hodgkin's disease. Br Med J 2:797-799, 1977
48. Read EJ, Keenan AM, Carter CS, etal: Kinetics of "‘indium-oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med. In press